Exactly there are very few options available for this unmet medical need.

Post hold

“We are pleased to announce that our Phase II-III study of leronlimab, in a population of patients with HIV and multi-drug resistant environments*, will also shortly be submitted for review. This study did achieve a* significant p-value for its Primary
Endpoint demonstrating the Efficacy of leronlimab in the multi-drug resistant population”

"This study could support the pursuit of leronlimab as an HIV antiviral should that opportunity once again make sense."

Before anyone says the MDR pop doesn’t make sense, it’s significant enough to bring in over hundreds of millions of dollars if not billions per year if we were to capture a small percentage of that market.

Money aside we should be able to treat these people the data speaks for itself. I’m sure the key opinion leaders Jay spoke with agree.